On the other hand, the plasma sHLA-G is frequently undetectable/low in PTC patients [20,41], and its levels were not influenced by any of the assessed markers in the tumor microenvironment (BRAF or HLA-G tumor expression, BRAFV600E, and TERT mutations), as reported in this series. This evidence concerns the gene BRAF and neoplasm.